CG Oncology Q1 net loss $34.5M; BLA submission on track for H2 2025

CG Oncology, Inc.

2025-Q1 EPS reported -$0.45 revenue$52,000

Net loss of $34.5M ($0.45/share) vs $16.9M ($0.36) a year ago; R&D spend rose to $27.5M.
Cash $688.4M as of March 31, 2025; expected to fund operations into first half of 2028.
BOND-003 Cohort C: 75.5% CR at any time; 24-month CR rate 42.3% by K-M; 97.3% progression-free at 24 months.
Cohort P: 90.5% high-grade recurrence-free survival at 3 and 9 months in BCG-unresponsive Ta/T1 disease.
Anticipates starting BLA submission for cretostimogene in HR BCG-unresponsive NMIBC in H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.